Why $CAPR is setting up for a massive short squeeze tomorrow (FDA BLA update + 15.5M Short Shares Trapped)
Wanted to throw this on everyone's radar because the setup brewing here post-market is insane.
$CAPR closed regular trading today at **$4.23**. Then Q2 earnings hit after-hours along with a game-changing regulatory update, and it shot up **60%+ to $6.75 - $7.70+**.
Here is why institutional shorts are trapped, why long funds will jump in, and why tomorrow could turn into a full-blown squeeze.
---
### 1. Why Tonight's Earnings Call Shattered the Bear Thesis
Shorts were betting heavily that Capricor was dead in the water after the AdCom concerns, hoping the company would face an immediate rejection or run out of cash.
Tonight’s Q2 earnings call completely eliminated that risk:
* **FDA Greenlights BLA Amendment:** Management explicitly confirmed the **FDA is open to reviewing an amended BLA** focusing on upper limb function (PUL 2.0 endpoint, $p=0.029$) for Deramiocel. The regulatory door is wide open again.
* **Massive Cash Runway ($237.9M Cash):** Capricor reported **$237.9 Million in cash, cash equivalents, and marketable securities**. Shorts can no longer rely on a bankruptcy or emergency dilution thesis.
* **Precedent is on Their Side:** The FDA routinely shows flexibility in rare Duchenne muscular dystrophy (DMD) indications when strong upper limb functional data exists (like Sarepta's Eteplirsen).
---
### 2. The Math Behind the 11M After-Hours Volume
We saw massive volume tonight with **~11 million shares traded in after-hours**. But don't let that number trick you into thinking shorts escaped.
In post-market trading, volume is heavily dominated by long momentum chasers, retail buyers, and high-frequency algos flipping the same pool of shares back and forth.
* **Realistic Estimate:** Even if you assume a generous **30% of that 11M volume was actual short covering (~3.3M shares)**, that still leaves **over 12.2 million shorted shares (~78.8% of the 15.58M short float) 100% trapped.**
---
### 3. Institutional Buyers & Shorts Will Capitalize on the Reversal
This isn't just a retail pump—institutional sentiment is shifting fast:
* **Institutional Shorts Buying Back:** Now that FDA approval is back on the table and bankruptcy risk is zero ($237.9M cash), holding a short position makes no fundamental sense. Shorts will be forced to buy back shares to cap their losses.
* **Long Funds Seeing the Value:** Long-oriented biotech funds that stayed on the sidelines during the AdCom overhang now see a massive de-risked opportunity with FDA alignment. As long funds start accumulating, they will absorb the remaining float, accelerating the squeeze on lingering bears.
---
### 4. Why the Main Session Will Force Their Hand
Most institutional funds don't slam market buy orders into thin after-hours order books to cover or build positions—doing so would drive the stock past $10+ instantly due to slippage.
They are sitting on massive unrealized losses, waiting for regular market hours liquidity to open up. When institutional volume hits during Pre-Market and the opening bell, forced short-covering combined with institutional long buying is going to run straight into a locked-up float.
---
**TL;DR:** Shorts loaded up to 34% of float (15.58M shares) expecting an FDA dead-end and cash crunch. Tonight's Q2 earnings revealed the FDA is willing to review an amended BLA, backed by $237.9M in cash runway. Even with 11M AH volume, ~12M+ short shares (~78%+) remain trapped with zero fundamental reason to stay short.